Pasithea Therapeutics Corp. · NASDAQ:KTTA
Pasithea Therapeutics — IPO Roadshow (June 2021)
15 slides from Pasithea Therapeutics's IPO roadshow presentation, Jun 22, 2021
Slide 1: Corporate Presentation
Corporate Presentation 1 CO P YRIGH T © 202 1 P A SI T H E A
Slide 2: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualific
Slide 3: Offering Summary
OFFERING SUMMARY 3 CO P YRIGH T © 202 1 P A SI T H E A Issuer: Pasithea Therapeutics Corp. Proposed Exchange / Ticker: Nasdaq Capital Market / KTTA Offering Type: Underwritten Initial Public Offering Securities Issued: Common Stock Gross Offering Proceeds (including Over - Allotment): $20,000,000 Ov
Slide 4: Introduction to Pasithea Therapeutics
INTRODUCTION TO PASITHEA THERAPEUTICS Pasithea Therapeutics is a biotech company at the forefront of neuroscience research Complementary Two - Pronged Business Model Improving treatment options for those affected by mental illness 1. PRIMARY FOCUS: Drug development: Discovering new, effective treatm
Slide 5: Investment Highlights
INVESTMENT HIGHLIGHTS Large Addressable Market With Few Options for Adequate Help Today Capital - Light Infrastructure Diversified Revenue Stream with Significant Revenue and EBITDA Growth Potential Seasoned Leadership Team with Expertise in Neuroscience & Psychopharmacology Dr. Lawrence Steinman, E
Slide 6: Large and Growing Addressable Market
LARGE AND GROWING ADDRESSABLE MARKET 64.6 Million Estimated number of adults suffering from some type of mental health issue in the U.S. 1 US$16.1 Trillion Lost between 2010 and 2030 due to mental health conditions 2 US$19.2 Billion Estimated size of anxiety and depression market by 2027 3 Up 33% De
Slide 7: The Stark Reality of the Global Treatment Gap
THE STARK REALITY OF THE GLOBAL TREATMENT GAP Overall Dropout HIGH - INCOME LOW - INCOME 1 in 5 people 3 1 in 27 people 3 COUNTRIES TREATM EN T RECEIVED OVERALL DROP OUT RATE: 31.7% 4 1 Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004;82(1
Slide 8: Even Those Who Do Get Treatment Face Challenges
EVEN THOSE WHO DO GET TREATMENT FACE CHALLENGES Current treatments for psychiatric disorders are inadequate. Conventional medicines have low success rates in long - term treatment, and New types of drugs are limited by working through the same mechanisms . DIZZINESS HEADACHES NAUSEA ERECTIL E DYSFUN
Slide 9: Primary Focus: Developing New Molecular Entities and/or Novel Biologic Drugs
PRIMARY FOCUS: DEVELOPING NEW MOLECULAR ENTITIES AND/OR NOVEL BIOLOGIC DRUGS Phase 1 Phase 2 Phase 3 Develop 3 lead compounds focused on psychiatric and neurological disorders Focuses on: • Targets that can be developed into a drug • Commercial potential of drug targets Candidate compounds will unde
Slide 10: Secondary Focus: Clinic Partnerships to Deliver Ketamine Treatments
SECONDARY FOCUS: CLINIC PARTNERSHIPS TO DELIVER KETAMINE TREATMENTS Provides intravenous infusions of ketamine to treat mental health disorders, such as Treatment - Resistant Depression (TRD) and Post - Traumatic Stress Disorder (PTSD) Gives immediate access to patients in the UK and US Capital - li
Slide 11: UK Clinic Partnership
UK CLINIC PARTNERSHIP Highlights: • Capital - light partnership with Zen Healthcare • Three locations in Marylebone, Knightsbridge, and Holborn • Provides immediate exposure in the UK • Existing management structure and qualified GPs, pharmacists, therapists and psychotherapists Deal Terms: • Agreem
Slide 12: US Partnership
US PARTNERSHIP NYC Base LA Base Deal Terms: • Plan to market and roll out nationwide 22.5K Pasithea pays IV Doc a fixed monthly fee of $22,500 Th e I V Doc 50,000 Patients 7 Years of operating Highlights: • Partnered with The IV Doc, a leading provider of administrative and support services to affil
Slide 13: Pasithea's Competitive Landscape in the Mental Health Sector
PASITHEA’S COMPETITIVE LANDSCAPE IN THE MENTAL HEALTH SECTOR 13 CO P YRIGH T © 202 1 P A SI T H E A
Slide 14: Improving Mental Health Treatments and Driving Shareholder Value
IMPROVING MENTAL HEALTH TREATMENTS AND DRIVING SHAREHOLDER VALUE Seasoned Leadership Team with Expertise in Neuroscience & Psychopharmacology Large Addressable Market With Few Options for Adequate Help Today Diversified Revenue Stream with Significant Revenue and EBITDA Growth Potential Capital - Li
Slide 15: Deal Contact
www.pasitheaclinics.com Deal Contact: Bryan Kobel Managing Director EF Hutton (646) 286 - 1962 bkobel@efhuttongroup.com 15 CO P YRIGH T © 202 1 P A SI T H E A